ORIGINAL RESEARCH article

Front. Cell. Infect. Microbiol.

Sec. Clinical Microbiology

Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1564488

This article is part of the Research TopicPathogenic Mechanisms and New Technology-Based Diagnostics for Bacterial InfectionsView all 8 articles

Comprehensive analysis of culture-negative periprosthetic joint infection with metagenomic next-generation sequencing

Provisionally accepted
Lan  LinLan LinJiayu  LiJiayu LiCanhong  ZhangCanhong ZhangJuncheng  LiJuncheng LiBaijian  WuBaijian WuZida  HuangZida HuangJianhua  LvJianhua LvMingzhong  LiuMingzhong LiuWenbo  LiWenbo LiWenming  ZhangWenming ZhangXinyu  FangXinyu Fang*
  • First Affiliated Hospital of Fujian Medical University, Fuzhou, China

The final, formatted version of the article will be published soon.

Objective: This study aimed to identify the risk factors and microbial profiles of patients with culture-negative periprosthetic joint infection (PJI) using metagenomic next generation sequencing (mNGS) and to compare the clinical characteristics and treatment outcomes of culture-negative PJI (CN PJI) with culture-positive PJI (CP PJI). Methods: A retrospective analysis was conducted on 223 patients who met the International Consensus Meeting criteria for PJI and underwent surgical treatment at our hospital between February 2013 and January 2023. Clinical and follow-up data, including microbiological culture results and mNGS findings, were collected. Based on culture results, patients were divided into the CP PJI and CN PJI groups. Risk factors and microbial profiles of CN PJI patients were summarized with the aid of mNGS results. Differences in clinical characteristics and treatment outcomes between the two groups were also analyzed.Results: Among the 223 patients, 168 were in the CP PJI group, and 55 were in the CN PJI group. Risk factors for negative cultures included polymicrobial infections, infections caused by rare pathogens, and prolonged antibiotic use prior to sampling. In the CN PJI group, over a quarter of cases involved polymicrobial infections (25.5%) or rare pathogen infections (38.2%), with Mycoplasma sp. being the most frequently identified rare pathogen (7.2%). Compared to the CP PJI group, the CN PJI group exhibited distinctly longer hospital stays (P<0.001), extended antibiotic use (P=0.02), and a higher rate of antibiotic-related complications (P=0.026). However, no significant difference was noted in reinfection rates between the two groups (P=0.412). Conclusion: CN PJI presents a unique microbial spectrum and distinct clinical therapeutic characteristics. mNGS offers a more comprehensive understanding of infecting microorganisms, particularly those often missed by conventional culture techniques. With advancements in sample collection, optimized culture methods, molecular diagnostic tools, and early targeted therapies, CN PJI may achieve clinical outcomes comparable to CP PJI.

Keywords: periprosthetic joint infection, negative microbiological cultures, metagenomic next-generation sequencing, Microbiology, Risk factors

Received: 21 Jan 2025; Accepted: 11 Apr 2025.

Copyright: © 2025 Lin, Li, Zhang, Li, Wu, Huang, Lv, Liu, Li, Zhang and Fang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Xinyu Fang, First Affiliated Hospital of Fujian Medical University, Fuzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.